from patients with atopic keratoconjunctivits (AVC)/vernal keratoconunctivitis (VKC) patients. In this study, we examined the roles of interaction between the conjunctival epithelial cells and mast cells.
Methods:
The interaction between human mast cells and conjunctival epithelial cells (HCjE) was investigated using a coculture model. Protein array analysis, ELISA and realtime PCR were carried out to test the interaction. Tissue samples (n=6) from Giant papillae were resected for therapeutic purposes, and subjected to immunohistological analysis of CCL2 expression. Recombinant CCL2 (10ng/ml) was reacted with the cultured human mast cells, and ultrastructural analysis was carried out. A ragweed (RW)-induced mouse experimental allergic conjunctivitis model was used to examine ccl2 mRNA expression and mast cell morphology.
Results: Protein array and real-time PCR analyses showed that CCL2 protein/mRNA expression was induced by mast cell-HCjE coculture. Upregulation of CCL2 mRNA was observed in mast cells, whereas in situ CCL2 expression was observed at the conjunctival epithelium of the giant papillae by immunohistochemistry. Ultrastructural analysis showed that recombinant CCL2 treatment induced piecemeal degranulation (PMD) in the mast cells. Ultrastructural analysis of tissues from the giant papillae showed PMD of mast cells within the conjunctival epithelial cells. The RW-induced experimental allergic conjunctivitis model showed increased ccl2 mRNA expression and PMD morphology in the conjunctivae.
Conclusions:
Mast cell-conjunctival epithelial cell interaction induces CCL2 expression and subsequent PMD.
Introduction
Mast cell activation and migration within and around the conjunctival epithelium is one of the histopathological features of severe chronic allergic conjunctivitis, atopic keratoconjunctivitis (AKC) 1 and vernal keratoconjunctivitis (VKC). 2 In this study we investigated possible interactions of mast cells and conjunctival epithelial cells using in vitro coculture models, and we found that CCL2 expression in mast cells was upregulated by coculture. A previous report showed that CCL2 could induce piecemeal degranulation (PMD) in basophils. 3 PMD and anaphylactic degranulation are known as two distinct types of mast cell degranulation. 4 5 Anaphylactic degranulation is a degranulation style with antecedent granule-to-granule and/or granule-to-plasma membrane fusions. On the other hand, gradual emptying of cytoplasmic secretory granules in the absence of granule-to-granule or granule-to-plasma membrane fusion events is observed in PMD.
Previously, we reported that 34 of 168 mast cells observed in the giant papillae of eight eyes obtained from VKC patients showed PMD, whereas only 28 of the 168 mast cells had the morphology of anaphylactic degranulation. 6 These results suggested that not only anaphylactic degranulation but also PMD might play some roles in the pathophysiology of AKC and VKC. In this study, we investigated the roles of mast cells and epithelial cells interactions, as well as the roles of PMD and CCL2 expression in mast cells, in the pathophysiology of AKC/VKC.
Material and Methods
Coculture model of mast cells and conjunctival epithelial cells. Human mast cell line LAD2 was provided by Dr. Arnold Kirchenbaum (NIH) and maintained as previously described. 7 Human peripheral blood derived mast cells (p-mast) were raised and maintained as previously described. 8 The human conjunctival epithelial cell line HCjE was provided by Prof. Ilene Gipson (Schepens Eye Research Inst., MA) and maintained as previously described. 9 Coculture models of these there cells were made using Costar
Transwell permeable supports (for 12-well culture dishes).
Antibody array analysis and ELISA analysis using culture supernatant. For antibody array analysis, the culture supernatant was incubated with Human Inflammation Array NO.3 (Ray Biotech Inc., Norcross, GA) according to the manufacturer's protocol.
The results were visualized and quantified using an LAS 3000 image ware (Fuji Film, Tokyo Japan). Human CCL2 ELISA was carried out using a Quantikine CCL2 ELISA kit (R&D Systems, Minneapolis MN) according to the manufacturer's protocol.
Giant papillae and control conjunctivae samples. Giant papillae were resected for therapeutic purposes from 5 patients, 3 with AKC and 2 with VKC, and control conjunctival tissue was biopsied from 8 conjunctivochalesis patients during resection surgery after obtaining written informed consent as previously described. 10 Additional giant papillae were obtained from 2 AKC and 4 VKC patients for immunohistochemical analysis. All of the procedures were approved by the ethics committees of the Juntendo University School of Medicine and Kyoto Prefectural University of Medicine, and the study was conducted in accordance with the tenets of the Declaration of Helsinki. AKC was defined as a bilateral chronic inflammation of the conjunctiva and eyelids associated with atopic dermatitis, and VKC was defined as a chronic, bilateral, conjunctival inflammatory condition found in individuals as previously described.
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Reverse-transcription (RT) and real-time PCR. Total RNA was extracted from the cultured cells and tissues of the giant papillae using a NucleoSpin II RNA isolation kit (Macherey-Nagel GmbH & Co. KG, Duren, Germany), and cDNAs were prepared from 1μg of total RNA using random primers and the RevaTra-Ace reverse transcriptase (both from Toyobo, Tokyo Japan) according to the manufacturer's protocol. We used TaqMann® real-time PCR probes and primers specific for human CCL2 Immunohistochemical analysis. The specimens form the giant papillae were immediately fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 3 hours. After washing with 30% sucrose in PBS, the tissues were frozen in Optimal
Cutting Temperature (OCT, Sakura Finetek, Tokyo, Japan) compound using liquid nitrogen. Then 5μm frozen sections were made and air-dried. Immunohistochemical staining was performed according to the previously described methods. 11 A mouse anti-human CCL2 monoclonal antibody (R&D) was used as a primary antibody (10μg/ml). For mast cell staining, a rabbit anti-FcεRIβ antibody was prepared and used as previously described. Ultrastructural analysis of human cultured mast cells. P-mast cells were stimulated with 20ng/ml recombinant human CCL2 (purchased from Peprotech, London, UK) for 3 min 3 and fixed with 2.5% glutaraldehyde and postfixed with 2% osmic acid. HCjE cocultured p-mast cells were also prepared for ultrastructural analysis after 24-hour coculture experiments. For negative control, recombinant human CXCL8 (Peprotech; 20ng/ml, for 3min) stimulated p-mast cells, and crosslinked p-mast cells using human IgE (1μg/ml, purchased from Chemicon/Millipore, Billerica, MA) and rabbit anti-IgE (1μg/ml, from Dako Japan, Kyoto, Japan) were prepared. The samples were embedded in epoxy resin and ultrathin sections (60-80nm) were made. The ultrathin sections were then examined using a transmission electron microscope (7000-100; Hitachi
High-Technologies, Tokyo, Japan).
Alum ragweed induced experimental allergic conjunctivitis
Alum ragweed (RW)-induced experimental allergic conjunctivitis models were prepared as previously described using male BALB/C mice at the age of 10-12 weeks (SLC, Hamamatsu, Japan). 12 The expression of ccl2 mRNA was quantified for mouse Table 1 .
Significantly higher CCL2 mRNA expression was observed in tissues from giant papillae than in conjunctivochalesis tissue samples. Five samples from giant papillae and eight conjunctivochalesis samples (Table 2) were collected and cDNA was prepared.
Real-time PCR analysis showed significantly increased CCL2 mRNA in the samples from giant papillae compared to the conjunctivochalasis samples. (Figure 5 ) We found few CCL2/FcεRIβ double-positive mast cells ( Figure 4B ) by immunohistochemical analysis. Although the main CCL2 mRNA-producing cells were mast cells (Figure 2A ), CCL2 protein was also secreted from mast cells as we found in culture supernatant samples ( Figure 1D ). Therefore we hypothesize that continuous CCL2 secretion from mast cells was the reason we found few CCL2/FcεRIβ double-positive mast cells. This discrepancy between abundant CCL2 mRNA expression and poor CCL2 retention in mast cells was reported previously.
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We obtained tarsal giant papilla tissues from refractory AKC/VKC patients, all of whom were treated with topical dexamethasone eye drops for at least 4 weeks (Table 1) , so treatment may have downregulated the CCL2 expression as reported previously 18 .
Nonetheless, significantly higher CCL2 mRNA expression in samples from giant papillae than in conjunctival tissues obtained from conjunctivochalesis patients was observed by real-time PCR analysis ( Figure 5 ).
Interestingly, the report of Gordon also showed that CCL2 expression in a PCA model was dependent on mast cells because of significantly reduced CCL2 expression in the skin of mast cell-deficient mice (W/Wv) during the PCA reaction. 15 Their results suggesting that interaction between mast cells and other components of conjunctival cells (including conjunctival epithelial cells) could upregulate CCL2 expression during allergic reactions agreed with our results in this study.
To further elucidate the role of CCL2 protein in the pathophysiology of AKC/VKC, we examined the activation pattern of mast cells with special reference to PMD. We found that recombinant CCL2 stimulation ( Figure 6B and 6F) as well as HCjE coculture procedures ( Figure 6C and 6G) could induce PMD in cultured mast cells in vitro. We also tried to inhibit the effect of CCL2 by adding a CCR2 inhibitor (RS504393 from TOCRIS Bioscience) to the coculture model, and found partial inhibition of the PMD phenomenon (data not shown). Consistent with the results of a previous report 19 , p-mast cells stimulated with another chemokine (CXCL8) did not show PMD morphology ( Figure   6H ). This result also supported the specificity of the CCL2-induced PMD phenomenon.
Although we could not deny the possibility of other conjunctival epithelial cell-derived mast cell activators, CCL2 in the coculture medium played some roles in PMD.
Continuous studies are ongoing in our laboratory to elucidate possible additional activators. We also found PMD in the intraepithelial mast cells of a VKC patient, showing the relevance of PMD to the pathophysiology of VKC (Figure 7 ). In our previous study, 20% of the mast cells in the giant papillae samples showed the PMD morphology and 17% of the mast cells in the giant papillae samples showed anaphylactic degranulation in VKC patients. 6 These results suggested the importance of PMD and subsequent slow/persistent mediator release 20 during chronic allergic keratoconjunctivitis. The magnitude of inflammation with PMD seems to be smaller than with anaphylactic degranulation; however, the PMD reaction lasts longer without IgE crosslinking by the antigen 5 . On the other hand, the mediator release from mast cells is not long lasting in the case of anaphylactic degranulation because it needs some time to regain the cytoplasmic A study by Miyazaki et al. showed that CCL2 protein was expressed in the conjunctival epithelium of mouse experimental allergic conjunctivitis and CCL2 subconjunctival injection induced mast cell degranulation. 24 Our results are consistent with their findings.
They also reported that blocking the CCL2-CCR2 signaling cascade could attenuate signs and symptoms of the acute phase of experimental allergic conjunctivitis. 24 Further experiments analyzing RW-induced experimental allergic conjunctivitis using mast cell-deficient mice to clarify mast cell-conjunctival epithelial cell interactions are now ongoing.
In conclusion, we showed that mast cell-conjunctival epithelial cell interaction could induce higher CCL2 expression and PMD in cultured human mast cells, which also observed in situ samples of chronic allergic conjunctivitis. These results suggested that suppression of CCL2-CCR2 signaling cascades might be useful for alternative therapy for severe chronic allergic conjunctivitis. staining (E) and control mouse IgG 1 antibody staining using two adjacent sections (F).
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